重组人血管内皮抑素不同给药方式的研究进展

Research Progress of Different Administration Routes of Recombinant Human Endostatin

重组人血管内皮抑素(Endostar)-恩度,是我国自主研发的一种血管内皮抑制素。由于它传统的给药方式的给药时长、血药浓度波动大,患者们常常依从性较差且心脏细胞毒性具有较高反应。然而恩度的腔内灌注给药、瘤内直接注射以及微量泵持续泵入等新型给药方法有着更好的疗效和更高的安全性,这为拓宽血管内皮抑素的治疗适应症、提高患者的依从性、生活质量和疗效具有重要的临床意义。

Recombinant human endostatin(Endostar)is a kind of vascular endostatin independently developed in our country.Due to it is traditional routes of administration,the length of administration and the large fluctuation of blood drug concentration,which patients often have poor compliance and high response to cardiac cytotoxicity,However,new administration routes of endostar have better efficacy and higher safety by intraluminal infusion,intratumoral direct injection and continuous pumping with micropump and so on.It is important clinical significance for broadening the therapeutic indications of endostatin and improving compliance and efficacy of patient.